SHD
Skin Health and Disease
Review Article

Skin Health and Disease 2025; 00:1-5
https://doi.org/10.1093/skinhd/vzaf099
Advance access publication date: 30 December 2025

A historical review of mycosis fungoides: from Alibert to mogamulizumab
Nicholas A Johnson ,1 Opeoluwa Fariyike ,1 Khaylen Mistry ,1·2 Zoe Venables1-2 and
Nick J Levell1-2
'Norwich Medical School, University of East Anglia, Norwich, UK
2Department of Dermatology, Norfolk and Norwich University Hospital, Norwich, UK
Correspondence: Nicholas A. Johnson. Email: nicholas.johnson@uea.ac.uk
Abstract
In 1806, French physician Baron Jean-Louis Alibert saw a man with a desquamating rash and skin tumours. Alibert considered this to be a variant of yaws. In 1829 Alibert named the condition mycosis fungoides (MF), meaning 'mushroom-like fungal disease'. Over 100 years later, French dermatologist Albert Sézary published papers from 1938 to 1949 detailing a mysterious disease containing 'cellules monstrueuses’, describing cutaneous 'monster cells'. In 1961, these clinical findings were collated together into 'Sézary syndrome'. In the 1870s English dermatologist William Tilbury Fox published a dermatology atlas detailing cases similar to what we know now as MF, with the name 'fibroma fungoides'. The atlas described MF as a type of fungus, before giving a description of yaws and painting a clinical picture that differed from that of a lymphoma. Over the twentieth century, our understandings of the origins of MF were changing and by 1975 the classification system and term we now recognize as cutaneous T-cell lymphoma (CTCL) was developed. Neoplastic cells have been thought to arise from chronic activation of Τ cells via antigen-presenting cells due to inappropriate cytokines and C-C chemokine receptors. In 2018, the World Health Organization and European Organisation for Research and Treatment of Cancer officially recognized four variants of MF. These are the classic Alibert-Bazin variant and its three variants: folliculotropic MF, pagetoid reticulosis and granulomatous slack skin. Developments in immunohistochemistry for the T-cell receptor gene in the 1990s improved the diagnosis of CTCL; however, diagnosis is still challenging. Advanced MF therapies have evolved from cytotoxic chemotherapy to novel monoclonal antibodies such as mogamulizumab, targeting proteins on T-cell lymphoma cells.

Accepted: 28 October 2025
© The Author(s) 2025. Published by Oxford University Press on behalf of British Association of Dermatologists. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.Org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Downloaded from https://academic.oup.com/skinhd/advance-article/doi/10.1093/skinhd/vzaf099/8407374 by East Anglia University user on 09 January 2026

First understandings of mycosis fungoides, and its clinical diagnosis
Since its first description in 1806 by French dermatologist Baron Jean-Louis Alibert (1768-1837), there has been confusion about the classification and diagnosis of mycosis fungoides (MF). A 56-year-old man named 'Lucas' was treated by Alibert for a desquamating rash and skin tumours, which Alibert termed as 'pian fongoide'.1 The term 'pian' was used by European physicians to describe yaws (Treponema pallidum subspecies pertenue),2 while 'fongoide' described mushroom-like growth. Alibert detailed an ailment that developed small tubercles like a potato or mushroom.3 Alibert first used the term 'mycosis fungoides' in 'Monographe des Dermatoses' in 1835 for the same patient (Figure 1).4 This terminology may have caused confusion regarding a possible infective, either fungal or treponemal, aetiology of MF.
In 1852, William James Erasmus Wilson (1809-1884) from England described Alibert's comments on MF. Wilson disagreed with Alibert, classifying MF with molluscum contagiosum, then known as molluscum of Bateman.56
In 1862, Alibert's student, Pierre-Antioine-Ernest Bazin (1807-1878), described three progressive stages of MF: eczematoid, infiltrative and tumoural, which later became known as the 'Alibert-Bazin' type.7 By 1874, Wilson had given the condition the name 'eczema tuberculatum'.8
In 1877, English dermatologist William Tilbury Fox (1836-1879) published in Atlas of Skin Diseases four cases of 'fibroma fungoides'.9 Fox gave the opinion that fibroma fungoides existed separately from lymph adenomas, epitheliomas, contractile keloids and MF of the French, as described by Alibert. A summary of these cases, and their key descriptions, can be found contrasted against Alibert's 'pian fongoide' in Table 1.
Confusion about the cause and origin of MF was widespread in the early and mid-nineteenth century as diagnosis was by visual examination. In the absence of precise diagnostic criteria and confusing nomenclature, many cases of MF were likely misdiagnosed.
Diagnosis of MF improved in the late nineteenth century with innovation of histopathological techniques. Louis- Antoine Ranvier (1835-1922) demonstrated reticular lymphoid tissues in MF in 1875.7 In 1887, French dermatologist Jean Ferdinand Darier (1856-1938) described 'Darier's epidermal nests', later renamed 'petits nids cellulaires'.10
In 1885, Émile Charles Achille Vidal (1825-1893) and Louis- Anne-Jean Brocq (1856-1928) documented MF 'd'emblee',

Figure 1 (a) Early illustration of fibroma fungoides taken from Tilbury Fox's Atlas of Skin Disease, 1872, which may represent mycosis fungoides (MF). Credit: Wellcome Library, London, under the Public Domain Universal Licence (https://creativecommons.org/publicdomain/ mark/1.0/). (b) Early drawings of MF termed 'pian fongoide', taken from skin observed in 'Description des maladies de la peau observées à l'Hòpital Saint-Louis. Et exposition des meilleures méthodes suivies pour leur traitement / par’, J.L. Alibert 1806. Credit: Wellcome Library, London, under the Creative Commons Attribution Lisence (https:// creativecommons.org/licenses/by/4.0/). (c) In J.L. Alibert, Arbre Des Dermatoses in 'Monographie des Dermatoses', 1835, MF is grouped with syphilis. Credit: Reproduced from a copy of Monographie des Dermatoses gifted to author N.J.L.

in which tumours were the first cutaneous manifestation - instead of being preceded by eruptions or infiltrations.7 In 1892, Francois Henri Hallopeau (1842-1919) and Ernest Henri Besnier (1831-1909) described erythroderma before the appearance of tumours.7 Pautrier microabscesses were credited to French dermatologist Lucien Marie Pautrier (18761959) in 1927, at the New York Society of Dermatology.10-12
French dermatologist Albert Sezary (1880-1956) published papers from 1938 to 1949 detailing a variant of MF with erythroderma and 'cellules monstrueuses’, or 'monster cells', in the blood.13 In 1961, these clinical findings were collated together into 'Sézary syndrome' (SS) and the cutaneous presence of 'mononuclear cells' was identified.14
Marvin A. Lutzner (unknown dates) and Richard L. Edelson (1944-) coined the term and classification of cutaneous T-cell lymphoma (CTCL) in 1975, allowing for unity as the term encompassed both MF and SS.15 However, MF diagnosis is often still delayed due to similarities in clinical presentation to common conditions such as psoriasis, eczema and tinea infections.16
Advancement and evolution of diagnosing and understanding the aetiology of mycosis fungoides
The distinct yet progressive stages of MF, coupled with limited diagnostic techniques, led to further confusion about its origin. Potential triggers of MF such as environmental and/or occupational exposure to solvents, genetic malformations and infectious causes, such as truncated human T-cell lympho- tropic virus (HTLV)-1, have been proposed and rejected.17-21
In the mid-twentieth century, the advent of flow cytometry and immunohistochemistry revolutionized MF diagnosis by identifying its T-cell origin and demonstrating antigen markers. In 1968, Lutzner used electron microscopy to comment on the irregularity of SS and MF cell nuclei, and the serpentine nature of SS nuclei, leading to the naming of Lutzner cells in the 1970s.22·23 Electron microscopy in 1980 was used to visualize the morphology of viruses such as HTLV, then thought to be involved in MF pathogenesis.24 In 1985 the Southern blot test demonstrated the monoclonal- ity of MF cells, and by 1987 immunohistology had helped identify the presence of CD30 antigens on MF cells.2526 The 1990s saw the polymerase chain reaction identify T-cell receptor arrangements specific to MF cells.27 However, the laboratory diagnosis of MF remains challenging.28.29

Table 1 Details and descriptions from Alibert's and Fox’s reports on patients with mycosis fungoides

Patient number	Date of case	Author	Book	Sex/age (years) if disclosed	Key term(s) to describe lesions	Final diagnosis	
Patient 1 ('Lucas')	1806	J.L. Alibert	De la peau observe a LHospital St Louis	Male, 56	Small tubercles	Pian fongoide. Illustration available in Figure 1(b)	
Patient 2	1871	W. Tilbury Fox	Atlas of the Skin 1875	Male, N/A	Without distinct granulations, fungal 'excrescences' Fibrocellular tissue	Fibroma fungoides	
Patient 3	Unknown	W. Tilbury Fox	Atlas of the Skin 1875	Female, N/A	Fibromatous tumours
Fibrocellular tissue	Fibroma fungoides/ lymphadenoma/'mycosis of the French'	
Patient 4	Unknown	W.Tilbury Fox	Atlas of the Skin 1875	N/A, child	Fibrocellular tissue Fleshy masses resembling half-ripe black grapes	Fibroma fungoides	

N/A, not available.

Downloaded from https://academic.oup.com/skinhd/advance-article/doi/10.1093/skinhd/vzaf099/8407374 by East Anglia University user on 09 January 2026

In MF, malignant Τ cells express cutaneous lymphocyte- associated antigen (CLA) and C-C chemokine receptors

Clinical variants	First clinical description of variant	Origin of term	
Alibert-Bazin
Pagetoid reticulosis (Woringer- Kolopp disease)
Folliculotropic
Granulomatous slack skin	1806: Alibert, later commented upon by Bazin
1939: Frederic Woringer (1903-1964) and
Pierre Kolopp34
1960: Hans-Georg Piper (1911-1969)35
1973: Jacinto Convit (1913-2014)36	Named from Alibert's and Bazin's contributions
1973: term proposed by Otto Braun-Falco (1922-2018)34
1985: term 'follicular’ mycosis fungoides proposed by
Sun-Yong Kim35
1978: term 'granulomatous cutis laxa' proposed by
Albert Bernard Ackerman (1936-2008)36	

Table 2 Clinical variants of mycosis fungoides and their origin

(CCRs). CLA+ Τ cells migrate to the skin through the help of cytokines, from sources such as keratinocytes.30 One of the important CCRs seen in MF is CCR4 and its ligand CCL17. They are involved in the apprehension of Τ cells and increasing prosurvival factors such as phosphatidylinositol-3-kinase, allowing these Τ cells to become resistant to apoptosis.31 MF cells can lack receptors such as CD7, CD5 and CD2, and malignant Τ cells congregate around Langerhans cells - seen as Pautrier microabscesses.30 Patients with MF have higher serum interleukin (IL)-7 and IL-15, which have roles in memory T-cell proliferation.32
In 2018, the World Health Organization and European Organisation for Research and Treatment of Cancer officially recognized four variants of MF (Table 2).33
How has mycosis fungoides management evolved?
As MF was confused as a variant of yaws/syphilis in the early nineteenth century, treatments may have included various herbal compounds, arsenic, atoxyl, sodium caso- dylate, potassium iodide and mercury.37
Fox's nineteenth-century treatments for MF (as fibroma fungoides) included hygienic regimens, nutritious diets and nourishment, unspecified tonics and astringents applied directly to the sores.9
The twentieth and twenty-first centuries brought many advancements in the management of MF (Table 3). Many treatments listed in Table 3 are still used in 2025.68 Psoralen and ultraviolet A, total skin electron beam therapy and topical nitrogen mustards are still indicated in both early- and advanced-stage management, as monotherapy or in conjunction.30

Treatment	Inception and first clinical use	First use in MF	
Radiotherapy	1896: Used to treat malignancy, a year after the discovery 1951: TSEBT used in MF39 and later in other T-cell of X-rays38	lymphomas40	
NM gas and mechlorethamine	1946: Clinical pharmacologists Louis Goodman and Alfred 1959: MF treated with topical mechlorethamine at Gilman used NM-based compounds such as methyl-bis	Cleveland clinic by John R. Haserick and Joseph Η.
(beta-chloroethyl) amine to manage Hodgkin lymphoma,	Richardson:42 alkylating agent with a strong
leukaemia and other malignancies41	antiproliferative effect43	
Photochemotherapy	1948: A.M. el-Moft used purified 8-MOP for vitiligo.44	1976: Fitzpatrick treated MF.47 In the 1970s and 1980s, Thomas B. Fitzpatrick researched and developed	trials of other photochemotherapeutic agents.43-50 In 1989, psoralens,45 and by 1974 with John A. Parrish coined the a trial ran by Frederic J. Kaye compared radiation therapy term PUVA40	and chemotherapy with topical PUVA and found no improved prognosis51	
Interferons	1957: First named and described.52 1974: Jordan U.	1984: Paul A. Bunn Jr described efficacy of high-dose
Gutterman first clinical trial of IFN-a in cancer53	recombinant IFN-α in patients with CTCL54	
VAD	1962: Topical tretinoin and other VAD compounds were	1983: John F. Kessler uses isotretinoin in CTCL.56 1999:
used in malignancies and hyperkeratotic disorders55	bexarotene was approved by the FDA57	
HDACi	1969: Akira Inoue isolated histone deacetylases.53 1998:	2006: Vorinostat (SAHA) was approved by the FDA for
Victoria M. Richon found SAHA and m-CBHA effective	CTCL,60 followed by romidepsin in 200961
against MEL and cancer cells59	
Monoclonal antibodies	1986: The first monoclonal antibody, orthoclone ΟΚΤ3,	2002: Alemtuzumab, an anti-CD52, monoclonal antibody,
was used to reduce rejection in kidney transplantation.02 was first trialled in CTCL.04 2017: Brentuximab vedotin 2012: Mogamulizumab, an anti-CCR4, was first approved was approved by the FDA for CD30-expressing MF.65 2018: iη CCR4+ adult T-cell leukaemia/lymphoma03	Mogamulizumab was first licensed by the FDA,66 and in
2021 by NICE67	

Table 3 Treatments for mycosis fungoides: their inception and first description in managing mycosis fungoides (MF)

CBHA, carboxycinnamic acid bishydroxamide; CCR, C-C chemokine receptor; CTCL, cutaneous T-cell lymphoma; FDA, Food and Drug Administration; HDACi, histone deacetylases inhibitors; IFN, interferon; MEL, murine erythroleukaemia; 8-MOP, 8-methoxypsoralen; NICE, National Institute for Health and Care Excellence; NM, nitrogen mustard; PUVA, psoralen and ultraviolet A; SAHA, suberoylanilide hydroxamic acid; TSEBT, total skin electron beam therapy; VAD, vitamin A derivatives.

Downloaded from https://academic.oup.com/skinhd/advance-article/doi/10.1093/skinhd/vzaf099/8407374 by East Anglia University user on 09 January 2026

In recent years monoclonal antibodies such as mogamulizumab have improved progression-free survival rates in MF.69 Mogamulizumab targets the CCR4 receptor, which - with its complementary CCL17 ligand - inhibits dermal migration of MF cells.70 Treatments for MF continue to improve, and although it is understood that MF is not an infectious disease, infections such as Staphylococcus aureus can promote MF.71

Summary
Reflection on the past two centuries from Alibertto mogamulizumab offers insight into the challenges that accompany the aetiology, diagnosis, classification and management of MF. While MF management has improved, diagnosis is often delayed due to clinician and patient confusion caused by the similarities in presentation with common benign dermatoses. Further patient and clinician education must be done to optimize patient outcomes.
Funding sources
This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
Author contributions
Nicholas A. Johnson (Conceptualization [lead], Investigation [lead], Writing—original draft [lead], Writing—review & editing [equal]), Opeoluwa Fariyike (Investigation [supporting], Writing—original draft [supporting]), Khaylen Mistry (Writing—review & editing [equal]), Zoe Venables (Supervision [equal], Writing—review & editing [equal]) and Nick J. Levell (Supervision [lead]. Writing—original draft [supporting], Writing—review & editing [equal])
Conflicts of interest
N.L. is on the editorial board of Skin Health and Disease. K.M. is deputy editor of Clinical and Experimental Dermatology. Z.V. is an advisor/collaborator for Regeneron, Merck and SkinAnalytics.
Data availability
No new data were generated in this review.
Ethics statement
Not applicable.
Patient consent
Not applicable.
References
1		Alibert JL. Second genre: dermatoses contagieuses. In: Descriptions de la maladie de la peau observée à THopital SaintLouis (Alibert JL, ed.). Paris: Baillière, 1837; 200-4.
2		Radolf JD. Treponema. In: Medical Microbiology (Albrecht Τ, Baron S, Castro G et al., eds), 4th edn. The University of Texas Medical Branch at Galveston, 1996; chapter 36.
3		Wallach D, Tilles G. Dermatology in France. Paris: Pierre Fabre Dermo-Cosmétique, 2002.
4		Funk Warsaw of. Clinical studies on sarcomata of the skin. In: The British Journal of Dermatology (Morris M, Brooke HG, eds), vol. 1. Η.Κ. Lewis, 1888-9; 143-156.
5		Wilson Ε. On Diseases of the Skin. Philadelphia: Blanchard and Lea, 1852.
Machado FM, Salvador RB. Why avoid naming diseases after animals? The case of "Molluscum contagiosum". Trop Med Health 2024; 52:21.
Block JB, Edgcomb J, Eisen A et al. Mycosis fungoides. Natural history and aspects of its relationship to other malignant lymphomas. Am J Med 1963; 34:228-35.
Sequeira JH. Discussion on mycosis fungoides. Proc R Soc Med 1914; 7:190-204.
Fox Τ. Atlas of Skin Diseases. London: J. & A. Churchill, 1877.
Bhat RM, Madhumita M. Pautrier's microabscess: an eponym by mistake. Indian J Dermatol Venereol Leprol 2020; 86:747-9.
Giessinger J, LeBoit ΡΕ, Cribier B. Pautrier microabscess: a topic of great controversy. Am J Dermatopathol 2021; 43:848-9.
Cribier BJ. The myth of Pautrier’s microabscesses. J Am Acad Dermatol 2003; 48:796-7.
Steffen C. The man behind the eponym dermatology in historical perspective: Albert Sézary and the Sezary syndrome. Am J Dermatopathol 2006; 28:357-67.
Taswell HF, Winkelmann RK. Sézary syndrome - a malignant ret- iculemic erythroderma. JAMA 1961; 177:465-72.
Lutzner M, Edelson R, Schein Ρ et al. Cutaneous T-cell lymphomas: the Sézary syndrome, mycosis fungoides, and related disorders. Ann Intern Med 1975; 83:534-52.
Lebas E, Collins Ρ, Somja J et al. A comprehensive update of the atypical, rare and mimicking presentations of mycosis fungoides. Dermatol Ther (Heidelb) 2021; 11:1931-51.
Slodownik D, Moshe S, Sprecher Ε et al. Occupational mycosis fungoides - a case series. Int J Dermatol 2017; 56:733-7.
Bergallo M, Dapra V, Fava Ρ et al. DNA from human polyomaviruses, MWPyV, HPyV6, HPyV7, HPyV9 and HPyV12 in cutaneous T-cell lymphomas. Anticancer Res 2018; 38:4111-14.
Vafsanen Ε, Fu Y, Koskenmies S et al. Cutavirus DNA in malignant and nonmalignant skin of cutaneous T-cell lymphoma and organ transplant patients but not of healthy adults. Clin Infect Dis 2019; 68:1904-10.
Blaizot R, Ouattara E, Fauconneau A et al. Infectious events and associated risk factors in mycosis fungoides/Sézary syndrome: a retrospective cohort study. Br J Dermatol 2018; 179: 1322-8.
Bazarbachi A, Soriano V, Pawson R et al. Mycosis fungoides and Sézary syndrome are not associated with HTLV-I infection: an international study. Br J Haematol 1997; 98:927-33.
Lutzner MA, Jordan HW. The ultrastructure of an abnormal cell in Sezary's syndrome. Blood 1968; 31:719-26.
Petrozzi JW, Raque CJ, Goldschmidt H. Malignant lymphoma, reticulum cell type: ultrastructural and cytological demonstration of Lutzner cells. Arch Dermatol 1971; 104:38-44.
Poiesz BJ, Ruscetti FW, Gazdar AF et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980; 77:7415-19.
Flug F, Pelicci PG, Bonetti F et al. T-cell receptor gene rearrangements as markers of lineage and clonality in T-cell neoplasms. Proc Natl Acad Sci U SA 1985; 82:3460-4.
Ralfkiaer E, Bosq J, Gatter KC et al. Expression of a Hodgkin and Reed-Sternberg cell associated antigen (Ki-1) in cutaneous lymphoid infiltrates. Arch Dermatol Res 1987; 279:285-92.
Liebmann RD, Anderson Β, McCarthy ΚΡ et al. The polymerase chain reaction in the diagnosis of early mycosis fungoides. J PathoH997; 182:282-7.
Nashan D, Faulhaber D, Stander S et al. Mycosis fungoides: a dermatological masquerader. Br J Dermatol 2007; 156:1-10.
Ahn CS, ALSayyah A, Sangueza OP. Mycosis fungoides: an updated review of clinicopathologic variants. Am J Dermatopathol 2014; 36:933-51.

Downloaded from https://academic.oup.com/skinhd/advance-article/doi/10.1093/skinhd/vzaf099/8407374 by East Anglia University user on 09 January 2026

Vaidya Τ, Badri Τ. Mycosis Fungoides. Treasure Island, FL: StatPearls Publishing, 2025.
Hwang ST, Janik JE, Jaff ES et al. Mycosis fungoides and Sezary syndrome. Lancet 2008; 371:945-57.
Beyer M, Mobs M, Humme D et al. Pathogenesis of mycosis fungoides. J Dtsch Dermatol Ges 2011; 9:594-8.
Willemze R, Cerroni L, Kempf W et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019; 133:1703-14.
Dusan S, Zoran Β, Sonja V et al. Pagetoid reticulosis of Woringer- Kolopp. Dermatol Online J 2008; 14:18.
Kituashvili Τ, Urushadze Τ, Liluashvili S et al. A case report of fol- liculotropic mycosis fungoides: diagnostic criteria and treatment strategy. Cureus 2024; 16:e71994.
Goldsztajn KO, Trope BM, Lenzi MER et al. Granulomatous slack skin. Histopathology diagnosis preceding clinical manifestations by 12 years. J Dermatol Case Rep 2012; 6:108.
Castellani A. Note on the spirochaete of yaws (Spirochaeta pertenuis}. BMJ 1907; 2:1511-12.
Gianfaldoni S, Gianfaldoni R, Wollina U et al. An overview on radiotherapy: from its history to its current applications in dermatology. Open Access Maced J Med Sci 2017; 5:521-5.
Trump JG, Wright ΚΑ, Evans WW et al. High energy electrons for the treatment of extensive superficial malignant lesions. Am J Roentgenol Radium Ther Nucl Med 1953; 69:623-9.
Le Bourgeois JP, Haddad E, Marinello G et al. The indications for total cutaneous electron beam radiation therapy of mycosis fungoides. Int J Radiat Oncol Biol Phys 1987; 13:189-93.
Goodman LS, Wintrobe MM, Dameshek W et al. Nitrogen mustard therapy. Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. JAMA 1984; 251:2255-61.
Haserick JR, Richardson JH, Grant DJ. Remission of lesions in mycosis fungoides following topical application of nitrogen mustard. Cleve Clin Q 1983; 50:91-5.
Kim ΥΗ. Management with topical nitrogen mustard in mycosis fungoides. Dermatol Ther 2003; 16:288-98.
Mofty AMA, Trueb RM. Psoralen and ultraviolet A (PUVA) therapy in the treatment of mycosis fungoides. J Am Acad Dermatol 1978; 1:122-8.
Fitzpatrick ΤΒ, Pathak MA. Research and development of oral psoralen and longwave radiation photochemotherapy: 2000 B.C.-1982 A.D. Natl Cancer Inst Monogr 1984; 66:3-11.
Parrish JA, Fitzpatrick TB, Tanenbaum L et al. Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. Ν Engl J Med 1974; 291:1207-11.
Gilchrest ΒΑ, Parrish JA, Tanenbaum L et al. Oral methoxsalen photochemotherapy of mycosis fungoides. Cancer 1976; 38:683-9.
Gottlieb SL, Wolfe JT, Fox FE et al. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution. J Am Acad Dermatol 1996; 35:946-57.
Hodge L, Briffa DV, Warin ΑΡ et al. Photochemotherapy in mycosis fungoides. Br Med J 1977; 2:1257-9.
Pakkish JA, LeVine MJ, Fitzpatrick TB. Oral methoxsalen photochemotherapy of psoriasis and mycosis fungoides. Int J Dermatol 1980; 19:379-86.
Kaye FJ, Bunn PA Jr, Steinberg SM et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. Ν Engl J Med 1989; 321:1784-90.
53 Gutterman JU. Cytokine therapeutics: lessons from interferon a. Proc Natl Acad Sci U SA 1994; 91:1198-205.
54 Bunn ΡΑ, Foon ΚΑ, Ihde DC et al. Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med 1984; 101:484-7.
55 Plewig G, Kligman AM. Tretinoin (all-trans-retinoic acid, vitamin A acid). In: Acne and Rosacea, 2nd edn. Berlin: Springer-Verlag, 1993; 584-97.
56 Kessler JF, Levine N, Meyskens FL et al. Treatment of cutaneous T-cell lymphoma (mycosis fungoides) with 13-cis-retinoic acid. Lancet 1983; 321:1345-7.
57 Weaver CH. FDA Approves Bexarotene (Targretin) for Treatment of Cutaneous T-Cell Lymphoma. Available at: https://news.can- cerconnect.com/fda-approves-bexarotene-targretin-for-treat- ment-of-cutaneous-t-cell-lymphoma/ (last accessed 30 July 2025).
58 Inoue A, Fujimoto D. Enzymatic deacetylation of histone. Biochem Biophys Res Commun 1969; 36:146-50.
59 Richon VM, Emiliani S, Verdin Ε et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U SA 1998; 95:3003-7.
60 Mann BS, Johnson JR, Cohen MH et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007; 12:1247-52.
61 VanderMolen KM, McCulloch W, Pearce CJ et al. Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J Antibiot (Tokyo) 2011; 64:525-31.
62 Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. Mabs 2014; 7:9-14.
63 Quadri I, Reneau JC, Hanel W, Chung CG. Advancements in the treatment of mycosis fungoides and Sezary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors. Front Immunol 2023; 14:1291259.
64 Kyowa Kirin. Launch of POTELIGEO® (Mogamulizumab) Injection in Japan, a Therapeutic Antibody for Adult T-cell LeukemiaLymphoma (ATL). Available at: https://www.kyowakirin.com/ media_center/news_releases/2012/e20120529_02.html (last accessed 15 July 2025).
65 Richardson NC, Kasamon YL, Chen Η et al. FDA approval summary: brentuximab vedotin in first-line treatment of peripheral T-cell lymphoma. Oncologist 2019; 24:el80-7.
66 FDA Approves Mogamulizumab-kpkc for Mycosis Fungoides or Sezary Syndrome. Available at: https://www.fda.gov/drugs/ resources-information-approved-drugs/fda-approves-mogam- ulizumab-kpkc-mycosis-fungoides-or-sezary-syndrome (last accessed 15 July 2025).
67 National Institute for Health and Care Excellence (NICE). Mogamulizumab for Previously Treated Mycosis Fungoides and Sezary Syndrome. Available at: https://www.nice.org.uk/guid- ance/TA754 (last accessed 15 July 2025).
68 Sheern C, Levell NJ, Craig PJ et al. Mycosis fungoides: a review. Clin Exp Dermatol 2025; 50:2365-2375.
69 Kim ΥΗ, Bagot M, Pinter-Brown L et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol 2018; 19:1192-204.
70 Duvic M, Evans M, Wang C. Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. Ther Adv Hematol 2016; 7:171-4.
71 Willerslev-Olsen A, Gjerdrum LMR, Lindahl LM et al. Staphylococcus aureus induces signal transducer and activator
52
A, Lil
J. Virus interference. I. The ii
Proc R Soc Lond B Biol Sci 1957; 147:258-67.
of transcription 5-
miR-155 expression in cutaneous
T-cell lymphoma. J Invest Dermatol 2021; 141:2449-58.